Author name: Swaraj Paul Barooah

.

Patents do not hinder Access?

/ By / Patent

Recently, Mr. Ranjit Shahani, the president of Organisation of Pharmaceutical Producers of India (OPPI) and vice chairman and managing director of Novartis India, gave an interview to the Financial Express regarding the importance of patents to the pharmaceutical industry and its effects on access to medicines. I’d like to take this chance to react to his statements. I’ll be extracting certain excerpts but the full interview is available here (and it’s a quick read). Disclaimer: I’ll be focusing on the parts […]

Patents do not hinder Access? Read More »

Anand Sharma gives a No to Data Exclusivity

/ By / Data Exclusivity

Picture Credit: Kevin Dean from http://www.betaart.com As we’ve highlighted several times on this blog, the pharmaceutical lobby in EU and US have (through their governments) tried to push India into accepting many stronger IP rights, including data exclusivity. As we’ve also highlighted several times, data exclusivity has been consistently been opposed by the Indian Pharmaceutical Alliance as well as several NGOs; however we haven’t been as sure as to what position the government was going to take in the EU-India

Anand Sharma gives a No to Data Exclusivity Read More »

SpicyIP Tidbit: Google test pilots its Innovation Incubator program in SA

/ By / Innovation

While Google may be facing criticism for trying to take too much power into their own hands with respect to their digitalisation of orphan works (see Amlan’s upcoming post for more on this), I doubt they will face any such opposition in their efforts to empower others by fostering innovation in Africa. Google has launched Umbono (Zulu for “idea/vision”) , a technological innovation incubator at Cape Town, South Africa. In a  statement from Google, they say: “For six months, teams will enjoy free office

SpicyIP Tidbit: Google test pilots its Innovation Incubator program in SA Read More »

Informing the pharma innovation debate: Harmonised IP standards and its effects

/ By / Innovation, Patent

Image from here  [Since this is a more theoretical post, in the interests of our readers, I’m stating at the outset that this piece is essentially regarding policy questions that ought to arise while considering global drug innovation policies, either patents or otherwise. For the purposes of this post, I’m keeping the “access to medicines and drug innovation policy” debate as the context, and for purposes of convenience I am broadly dividing the parties in this debate into two sides

Informing the pharma innovation debate: Harmonised IP standards and its effects Read More »

March 2nd marks aggravated protests against FTA

/ By / Data Exclusivity

While the government continues to march on with the EU-India FTA, protester’s have also continued to voice their concerns over the impact that the IP provisions of the draft Agreement will have on making medicines inaccessible. March 2nd marked a day of protest by health activists from across India including PLHIV Networks and Network of People who use Drugs, as well as activists from affected countries such as Nepal, Indonesia, Thailand and Philippines who came to New Delhi to voice their concerns

March 2nd marks aggravated protests against FTA Read More »

SpicyIP Tidbit: Medicines Patent Pool in talks with Big Pharma

/ By / Patent

UNITAID’s Medicines Patent Pool which received it’s first patent late last year is now making more headway by entering into negotiations with several key HIV medicines patent holders. Patent pools work by allowing patent holders to share their IP with other parties via licences. The working of this patent pool in particular therefore relied on the key patent holders contributing their patents to the pool for it work. To the skeptics (me included) of how well this would work, there is

SpicyIP Tidbit: Medicines Patent Pool in talks with Big Pharma Read More »

Submissions invited for USTR’s 2011 Special 301 report

/ By / Uncategorized

The annual Special 301 report is something we’ve covered a bit in the past, and the 2011 edition will be coming out soon. The USTR is requesting comments and submissions to be made for the 2011 edition for the public hearing on March 2nd. The deadline for submitting these is February 15th. For those who don’t know about USTR’s Special 301 Report, it is a unilateral measure taken by the USTR which essentially ranks countries according to how much the

Submissions invited for USTR’s 2011 Special 301 report Read More »

Wikileaks on ACTA’s development

/ By / Uncategorized

Wikileaks: Giving a helping handImage from here Wikileaks, which first brought our attention to the ACTA back in mid 2008, has now brought attention to the history of how the ACTA came about. Expectedly, it shows that there had been explicit communication regarding the eventual imposition of TRIPS plus standards on developing countries. Somewhat surprisingly however, it appears that the EU behaved as rather weak negotiating party and were not completely happy with how the events unfolded. La Quadrature du Net  has come out

Wikileaks on ACTA’s development Read More »

India, South Africa gain from J&J-generic deal, Patent Pool loses out

/ By / Uncategorized

Johnson & Johnson’s subsidiary Tibotec has granted multiple non-exclusive licenses for a new HIV-AIDS treatment to generic manufacturers including Hetero Drugs Ltd, Matrix Laboratories Ltd from India and Aspen Pharmacare from South Africa. The drug in question, rilpivirine hydrochloride (TMC278)  is still pending approval however. Tibotec would recieve 2-5% of what is received for the pills. The press release by Tibotec is available here.  The licensing allows the Indian generic companies to manufacture, market and distribute TMC278 in Least Developed Countries, Sub-Saharan

India, South Africa gain from J&J-generic deal, Patent Pool loses out Read More »

EU-India closer to FTA-hampered public health regime?

/ By / Data Exclusivity

Draft IP chapter made available The chapter on IP in the draft EU-India FTA has been made publicly available for the first time. As Malini Aisola has pointed out in her blogpost at CIS, the draft shows India’s rebuff of EU’s stand on several key IP provisions. There is a copy of the draft available here for those interested. [CIS-India has also helpfully compiled a chart comparing the language put forth by India and that put forward by EU, available here]. There seems

EU-India closer to FTA-hampered public health regime? Read More »

Scroll to Top